- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Faculty Research and Publications /
- Effects of a Web-Based Patient Decision Aid on Biologic...
Open Collections
UBC Faculty Research and Publications
Effects of a Web-Based Patient Decision Aid on Biologic and Small Molecule Agents for Rheumatoid Arthritis : Results From a Proof-of-Concept Study Li, Linda C.; Shaw, Chris D.; Lacaille, Diane; Yacyshyn, Elaine; Jones, C. Allyson; Koehn, Cheryl; Hoens, Alison; Geldman, Jasmina; Sayre, E. C.; Macdonald, Graham G.; Leese, Jenny; Bansback, Nick
Abstract
Objective. To assess the extent to which ANSWER-2, an interactive online patient decision aid, reduces patients’ decisional conflict and improves their medication-related knowledge and self-management capacity. Methods. We used a pre–post study design. Eligible participants had a diagnosis of rheumatoid arthritis (RA), had been recommended to start using a biologic agent or small-molecule agent or to switch to a new one, and had internet access. Access to ANSWER-2 was provided immediately after enrollment. Outcome measures included 1) the Decisional Conflict Scale (DCS), 2) the Medication Education Impact Questionnaire (MeiQ), and 3) the Partners in Health Scale (PIHS). A paired t-test was used to assess differences pre and postintervention. Results. The majority of the 50 participants were women (n = 40), and the mean ± SD age of participants was 49.6 ± 12.2 years. The median disease duration was 5 years (25th, 75th percentile: 2, 10 years). The mean ± SD DCS score was 45.9 ± 25.1 preintervention and 25.1 ± 21.8 postintervention (mean change of -21.2 of 100 [95% confidence interval (95% CI) -28.1, -14.4], P < 0.001). Before using ANSWER-2, 20% of participants had a DCS score of <25, compared to 52% of participants after the intervention. Similar results were observed in the PIHS (mean ± SD 25.3 ± 14.8 preintervention and 20.4 ± 13.0 postintervention; mean change of -3.7 of 88 [95% CI -6.3, -1.0], P = 0.009). Findings from the MeiQ were mixed, with statistically significant differences found only in the selfmanagement subscales. Conclusion. Patients’ decisional conflict decreased and perceived self-management capacity improved after using ANSWER-2. Future research comparing the effectiveness of ANSWER-2 with that of educational material on biologic agents will provide further insight into its value in RA management.
Item Metadata
| Title |
Effects of a Web-Based Patient Decision Aid on Biologic and Small Molecule Agents for Rheumatoid Arthritis : Results From a Proof-of-Concept Study
|
| Creator | |
| Contributor | |
| Publisher |
Wiley Online Library
|
| Date Issued |
2018-02-06
|
| Description |
Objective. To assess the extent to which ANSWER-2, an interactive online patient
decision aid, reduces patients’ decisional conflict and improves their medication-related
knowledge and self-management capacity.
Methods. We used a pre–post study design. Eligible participants had a diagnosis of
rheumatoid arthritis (RA), had been recommended to start using a biologic agent or
small-molecule agent or to switch to a new one, and had internet access. Access to
ANSWER-2 was provided immediately after enrollment. Outcome measures included
1) the Decisional Conflict Scale (DCS), 2) the Medication Education Impact
Questionnaire (MeiQ), and 3) the Partners in Health Scale (PIHS). A paired t-test was
used to assess differences pre and postintervention.
Results. The majority of the 50 participants were women (n = 40), and the mean ± SD
age of participants was 49.6 ±
12.2 years. The median disease duration was 5 years (25th, 75th percentile: 2, 10
years). The mean ± SD DCS score was 45.9 ± 25.1 preintervention and 25.1 ± 21.8
postintervention (mean change of -21.2 of 100 [95% confidence interval (95% CI) -28.1,
-14.4], P < 0.001). Before using ANSWER-2, 20% of participants had a DCS score of
<25, compared to 52% of participants after the intervention. Similar results were
observed in the PIHS (mean ± SD 25.3 ± 14.8 preintervention and 20.4 ± 13.0
postintervention; mean change of -3.7 of 88 [95% CI -6.3, -1.0], P = 0.009). Findings from the MeiQ were mixed, with statistically significant differences found only in the selfmanagement subscales. Conclusion. Patients’ decisional conflict decreased and
perceived self-management capacity improved after using ANSWER-2. Future
research comparing the effectiveness of ANSWER-2 with that of educational material
on biologic agents will provide further insight into its value in RA management.
|
| Genre | |
| Type | |
| Language |
eng
|
| Date Available |
2021-05-21
|
| Provider |
Vancouver : University of British Columbia Library
|
| Rights |
Attribution-NonCommercial-NoDerivatives 4.0 International
|
| DOI |
10.14288/1.0398114
|
| URI | |
| Affiliation | |
| Citation |
Li LC, Shaw CD, Lacaille D, Yacyshyn E, Jones CA, Koehn C, Hoens AM, Geldman J, Sayre EC, Macdonald GG, Leese J, Bansback N. Effects of a Web-Based Patient Decision Aid on Biologic and Small-Molecule Agents for Rheumatoid Arthritis: Results From a Proof-of-Concept Study. Arthritis Care Res (Hoboken). 2018 Mar;70(3):343-352.
|
| Publisher DOI |
10.1002/acr.23287
|
| Peer Review Status |
Reviewed
|
| Scholarly Level |
Faculty; Researcher; Postdoctoral; Graduate
|
| Rights URI | |
| Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International